Steven Cohen (Trades, Portfolio)'s investment firm, Point72 Asset Management, has recently expanded its investment portfolio by adding shares of Caribou Biosciences Inc (NASDAQ:CRBU). On February 22, 2024, the firm acquired 4,432,602 shares of the biopharmaceutical company, reflecting a significant commitment to the healthcare sector.
SEATTLE, Feb. 22, 2024 (GLOBE NEWSWIRE) Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announced that the first patient has been dosed with Atossa’s proprietary Selective Estrogen Receptor Modulator (SERM), (Z)-endoxifen, in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (R